Johnson & Johnson has gained US FDA approval to market Caplyta as a treatment for depression, strengthening its neuropsychiatric portfolio and commercial strategy.

HUTCHMED has completed patient enrollment for its global Phase III trial of ORPATHYS® and TAGRISSO® in advanced NSCLC, advancing a pivotal chemotherapy-free option across Asia-Pacific.

Moberg Pharma and Karo Healthcare finalize a pan-European licensing deal for MOB-015 (Terclara®), targeting coordinated launches and market leadership in antifungal therapy.

Avanos Medical delivered strong Specialty Nutrition Systems growth and closed its acquisition of Nexus Medical, advancing innovation in neonatal and pediatric nutrition despite ongoing tariff pressures.

Global pharma companies set a new record by investing $48.5B in partnerships with Chinese biotechs in the first half of 2025, led by innovations in oncology and next-gen therapeutics.

Eli Lilly announces a $3 billion investment for a new oral medications manufacturing facility in the Netherlands, aiming to expand its European supply chain, create jobs, and deploy next-generation manufacturing technology.

Akeso has secured a fourth Breakthrough Therapy Designation from China NMPA for ivonescimab in first-line TNBC, expediting development and regulatory pathways.

UPS has finalized its $1.6 billion acquisition of Andlauer Healthcare Group, significantly expanding its pharma logistics infrastructure and services throughout North America.

The European Commission has awarded Bavarian Nordic a new framework procurement contract for up to 8 million doses of smallpox/mpox vaccines, enhancing Europe’s disease preparedness.

Mallinckrodt announces new research presentations on terlipressin for hepatorenal syndrome at the 2025 AASLD meeting, underscoring ongoing innovation in rare liver disease therapeutics.